ENDOMETRIAL METAPLASIA

This adverse event was reported 19 times

ENDOMETRIAL METAPLASIA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 FOLLITROPIN ALFA 1 0.0005
1 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE 1 0.0004
2 MIFEPRISTONE 1 0.0002
3 TAMOXIFEN CITRATE 1 0.0002
4 LETROZOLE 3 0.0000
5 PROGESTERONE 1 0.0000
6 LETROZOLE TABLETS 2 0.0000
7 ROSUVASTATIN CALCIUM 1 0.0000
8 ANASTROZOLE 1 0.0000
9 IBUPROFEN SODIUM 1 0.0000
See all drugs enriched for association with ENDOMETRIAL METAPLASIA

ENDOMETRIAL METAPLASIA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Progestin Antagonist [EPC] 1 0.0002
1 Progesterone [EPC] 1 0.0000
2 Aromatase Inhibitor [EPC] 4 0.0000
3 Copper-containing Intrauterine Device [EPC] 1 0.0000
4 Parathyroid Hormone Analog [EPC] 1 0.0000
5 Histamine-2 Receptor Antagonist [EPC] 1 0.0000
6 Microtubule Inhibitor [EPC] 1 0.0000
7 Interferon beta [EPC] 1 0.0000
8 Thiazide Diuretic [EPC] 1 0.0000
9 Platinum-based Drug [EPC] 1 0.0000
See all drug classes enriched for association with ENDOMETRIAL METAPLASIA